Azenta, Inc. (AZTA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$37.38-4.50%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · AZTA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
"While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."
Stated in 2 of 3 supplied quarters. Management reported: “In 2026, our priority is the transformation of our Multiomics business, with a focus on strengthening commercial execution, optimizing our operating footprint, and improving productivity through Azenta Business System.” “"While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“"While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."”
“In 2026, our priority is the transformation of our Multiomics business, with a focus on strengthening commercial execution, optimizing our operating footprint, and improving productivity through Azen…”
Given the updated 2026 outlook, we are extending the timeline of our long‑range plan targets from 2028 to 2029.
Stated in 2 of 3 supplied quarters. Management reported: “o Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2025.” “Given the updated 2026 outlook, we are extending the timeline of our long‑range plan targets from 2028 to 2029.”
“Given the updated 2026 outlook, we are extending the timeline of our long‑range plan targets from 2028 to 2029.”
“o Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2025.”
"While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."
Stated in 2 of 3 supplied quarters. Management reported: “We also generated strong free cash flow in the quarter, reflecting our continued focus on operational discipline and working capital management,” said John Marotta, President and CEO.” “Guidance for Continuing Operations for Full Year Fiscal 2026 ● The Company is reiterating its guidance for fiscal year 2026: o Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2025.”
“"While these results represent an encouraging step forward, our turnaround continues, and we remain focused on executing against our strategic priorities."”
“We also generated strong free cash flow in the quarter, reflecting our continued focus on operational discipline and working capital management,” said John Marotta, President and CEO.”
“These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth,” said Trey Mar…
Stated in a supplied disclosure. Management reported: ““These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth,” said Trey Martin, President, Multiomics at Azenta.” “Building on its trusted brand, scientific expertise, global commercial engine, and operational infrastructure, Azenta is expanding its capabilities through an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition of SynPlexity Inc., a synthetic biology company providing high-throughput gene libraries for biological discovery.”
Pursue organic revenue growth across continuing operations while managing the revised fiscal 2026 outlook.
Over the trailing year it converted -0.91x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
17 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.